Zimmer Biomet (ZBH) Morgan Stanley 22nd Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Morgan Stanley 22nd Annual Global Healthcare Conference summary
30 Jun, 2026Business performance and growth outlook
Achieved consistent mid-single-digit revenue growth and double-digit EPS growth over the past 10 quarters, with a strong product pipeline and operational improvements since 2018.
2024 growth remains robust, with Q2 showing 5.6% revenue growth and 10% EPS growth, despite recent challenges.
Committed to mid-single-digit revenue growth, EPS growing 1.5x faster, and free cash flow at least 100 basis points above EPS through 2027.
SET and Recon (hips and knees) businesses are expected to maintain strong growth, with new product launches and increased market penetration.
ASC (ambulatory surgical centers) segment is a major growth driver, with 40%-60% of cases shifting to this setting and a comprehensive portfolio now in place.
ERP implementation and financial impact
Migration from legacy ERP to SAP in July led to operational challenges, primarily affecting the U.S. and Canada, with the 'other' business category most impacted.
The ERP issue could impact up to 1% of annual sales in 2024, but mitigation plans are in place to limit EPS impact and protect critical investments.
Confident the ERP challenges will be resolved within 2024, with service levels expected to normalize by year-end.
No impact anticipated for 2025 and beyond, with robust growth still expected in core business areas.
Product innovation and market positioning
Launching 50 new products over the next 30-36 months, including Oxford Partial Cementless knee (U.S. launch by summer 2025) and Persona IQ short stem.
Regaining hip market share with new products (direct anterior stem, surgical impactors, navigation) and revised sales incentives.
Cementless and robotic knee penetration targeted to reach 50% by 2027, with current rollouts showing strong momentum.
ROSA Shoulder robot is a unique competitive advantage, with U.S. and European launches planned and strong clinical trial results.
Robotics, navigation, and mixed reality form a comprehensive digital strategy, with optionality for different customer needs and ongoing investments in AI and non-robotic platforms.
Latest events from Zimmer Biomet
- U.S. sales transformation and innovation drive a transition year, targeting stronger growth ahead.ZBH
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Shareholders approved all board proposals except the independent chairman request.ZBH
AGM 202628 May 2026 - Strong Q1 growth, innovation, and sales force transformation set the stage for future gains.ZBH
Bank of America Global Healthcare Conference 202619 May 2026 - Q1 2026 saw strong sales, higher EPS, and raised guidance fueled by innovation and acquisitions.ZBH
Q1 20261 May 2026 - 2026 guidance targets 1%-3% revenue growth amid Salesforce transformation and robust innovation.ZBH
Q4 202511 Apr 2026 - Annual meeting to vote on directors, auditor, pay, and board chair proposal.ZBH
Proxy filing1 Apr 2026 - 2025 saw robust growth, enhanced governance, and strong pay-for-performance alignment.ZBH
Proxy filing1 Apr 2026 - Q2 sales rose 3.9% (5.6% ex-FX) with 10% adjusted EPS growth, led by global and tech demand.ZBH
Q2 20242 Feb 2026 - Innovation, M&A, and new launches aim to double robotics and cementless knee penetration by 2027.ZBH
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026